254 related articles for article (PubMed ID: 30237154)
1. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Driessen C; Müller R; Novak U; Cantoni N; Betticher D; Mach N; Rüfer A; Mey U; Samaras P; Ribi K; Besse L; Besse A; Berset C; Rondeau S; Hawle H; Hitz F; Pabst T; Zander T
Blood; 2018 Nov; 132(19):2097-2100. PubMed ID: 30237154
[No Abstract] [Full Text] [Related]
2. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
Hitz F; Kraus M; Pabst T; Hess D; Besse L; Silzle T; Novak U; Seipel K; Rondeau S; Stüdeli S; Vilei SB; Samaras P; Mey U; Driessen C;
Blood Cancer J; 2019 Aug; 9(9):70. PubMed ID: 31455773
[TBL] [Abstract][Full Text] [Related]
4. Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients.
Zhang L; Mager DE
J Pharm Sci; 2019 Jan; 108(1):732-740. PubMed ID: 30472266
[TBL] [Abstract][Full Text] [Related]
5. Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
Maeno S; Koh S; Ichii M; Oie Y; Nishida K; Kanakura Y
Ann Hematol; 2019 Mar; 98(3):793-795. PubMed ID: 30645676
[No Abstract] [Full Text] [Related]
6. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
8. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H; Weisel K; Petrucci MT; Leleu X; Cafro AM; Garderet L; Leitgeb C; Foa R; Greil R; Yakoub-Agha I; Zboralski D; Vauléon S; Dümmler T; Beyer D; Kruschinski A; Riecke K; Baumann M; Engelhardt M
Leukemia; 2017 Apr; 31(4):997-1000. PubMed ID: 28074071
[No Abstract] [Full Text] [Related]
9. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
11. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
12. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
13. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.
Krečak I; Ruščić I; Zlatović JJ; Šupe M; Krečak MV; Gverić-Krečak V
Ann Hematol; 2021 Jun; 100(6):1623-1624. PubMed ID: 33404692
[No Abstract] [Full Text] [Related]
14. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Alodhaibi I; Ailawadhi S; Burbano GP; O'Brien PJ; Buadi FK; Hayman S; Kumar SK; Gonsalves WI
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):298-304. PubMed ID: 38220589
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
[No Abstract] [Full Text] [Related]
16. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
[No Abstract] [Full Text] [Related]
17. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
[No Abstract] [Full Text] [Related]
18. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
19. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
20. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
